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Treatment associated toxicityIntroduction: The CAO/ARO/AIO-94 phase-III-trial demonstrated a signiﬁcant improvement of preopera-
tive chemoradiotherapy (CRT) versus postoperative CRT on local control for UICC stage II/III rectal cancer
patients, but no effect on long-term survival. In this add-on evaluation, we investigated the association of
gender and age with acute toxicity and outcome.
Patients and methods: According to actual treatment analyses, 654 of 799 patients had received pre-
(n = 406) or postoperative CRT (n = 248); in 145 patients postoperative CRT was not applied. Gender,
age and clinicopathological parameters were correlated with CRT-associated acute toxicity and survival.
Results: The 10-year survival was higher in women than in men, with 72.4% versus 65.6% for time to
recurrence (p = 0.088) and 62.7% versus 58.4% for overall-survival (OS) (p = 0.066), as expected. For
patients receiving CRT, women showed higher hematologic (p < 0.001) and acute organ toxicity
(p < 0.001) in the entire cohort as well as in subgroup analyses according to pre- (p = 0.016) and
postoperative CRT (p < 0.001). Lowest OS was seen in patients without acute toxicity (p = 0.0271).
Multivariate analyses for OS showed that acute organ toxicity (p = 0.034) was beneﬁcial while age
(p < 0.001) was associated with worse OS.
Discussion: Female gender is signiﬁcantly associated with CRT-induced acute toxicity in rectal cancer.
Acute toxicity during CRT may be associated with improved long-term outcome.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 48–54Rectal cancer is one of the most frequent malignancies in the
western world and represents a major socioeconomic and health
issue [1]. After publication of the intergroup CAO/ARO/AIO-94
[Working Group of Surgical Oncology, Radiation Oncology and
Medical Oncology] phase III trial of the German Rectal Cancer
Study-Group (GRCSG) in 2004 [2], preoperative radiotherapy com-
bined with intravenous ﬂuorouracil (5-FU) chemotherapy (CRT),
total mesorectal excision (TME-surgery) [3], and postoperative
(adjuvant) chemotherapy (CTx) with 5-FU became the preferred
treatment for patients with locally advanced rectal cancer (clini-
cally staged as UICC stages II/III) in Germany as well as in many
other parts of Europe and the US [4–7]. As much as shown in other
randomized trials [8,9], preoperative multimodality therapy
signiﬁcantly improves treatment compliance (based on lowaccompanied toxicity in the overall population) as well as long-
term loco-regional control with low relapse rates (between 5%
and 10%), but the occurrence of distant metastases in up to 30%
of patients still remains the major mode of failure [1,2,7,10].
Therefore, different intensiﬁed CRT regimens, including induc-
tion [11,12] and concurrent multi-agent chemotherapy approaches
[13–18], are currently being tested in clinical trials for better con-
trol of systemic disease. The aim of these trials is to increase the
rate of histopathologically conﬁrmed complete tumor regression
(pCR) as an early surrogate marker and, in particular, to reduce
the occurrence of distant metastases to ﬁnally improve time to
recurrence (TTR) as well as overall survival (OS) [19,20].
Obviously, these approaches with intensiﬁcation of the
multimodality treatment bear risks to increase high-grade acute
hematologic as well as organ toxicity, too [15,21,22]. Great efforts
are being undertaken to identify subgroups of patients at such
higher risk of severe acute toxicity during CRT in order to avoid
treatment interruption. It is well known that any delayed or
H.A. Wolff et al. / Radiotherapy and Oncology 108 (2013) 48–54 49incomplete multimodality treatment will not only result in limited
patients’ compliance but also affects cancer-speciﬁc outcome [23].
From the clinical point of view, the identiﬁcation of reliable
parameters that predict both CRT-induced tumor response and
treatment-related toxicity would be a promising step toward an
individualized risk-adapted treatment for rectal cancer patients.
In this context, molecular markers are being tested extensively,
applying cost-intense technologies such as gene expression proﬁl-
ing [24,25]. In contrast, basic clinical parameters such as gender
and age have been largely neglected, but could help to stratify
for risk-adapted treatment approaches.
Recently, our ﬁrst monocentric analysis demonstrated a
signiﬁcantly higher proportion of acute organ toxicity in women
during preoperative CRT for locally advanced rectal cancer [26].
In order to validate this correlation within an independent and
large phase-III study population with long-term follow-up, we
now performed an unplanned analysis of a total of 799 eligible pa-
tients with UICC stage II/III rectal cancers, treated within the CAO/
ARO/AIO-94 trial [6]. We here provide exploratory subgroup
analyses of this trial to assess the correlation between gender,
age, CRT-associated acute toxicity and long-term outcome.
Patients and methods
This study represents a clinical add-on evaluation of the multicen-
tric, open-label, randomizedCAO/ARO/AIO-94phase III trial conducted
by the GRCSG [2]. All analyses were approved by the central and local
ethics committees, and each patient had provided written informed
consent. The design of the trial was reported previously [2,7].Patient eligibility and treatment
The trial included patients between 18 and 75 years of age with
histopathologically conﬁrmed locally advanced adenocarcinoma of
the rectum (clinically staged as UICC stages II/III) with the inferior
margin lower than 16 cm above the anal verge as assessed by rigid
rectoscopy [7].
Multimodality treatment consisted of either pre- or postopera-
tively applied radiotherapy (RT) with daily fractions of 1.8 Gy
(5 times/week) with a total dose of 50.4 Gy. In the postoperative
CRT arm, a boost of 5.4 Gy was applied to the tumor bed. The target
volume deﬁnition and radiation technique were deﬁned according
to the study protocol [2]. Chemotherapy (CTx) was administered
concomitantly to RT as continuous 120-h 5-FU infusion, applied in
the ﬁrst and ﬁfth week of RT (1000 mg/m2 on days 1–5 and 29–
33). Total mesorectal excision (TME) surgery was performed 4–
6 weeks after completion of neoadjuvant CRT. Adjuvant CTx started
4 weeks after TME-surgery or after completion of postoperative
CRT, respectively, and consisted of 4 cycles of 5-FU intravenous bo-
lus (500 mg/m2), applied on days 1–5, repeated from day 29.Acute organ toxicity
Initially, hematologic toxicity as well as acute organ toxicity of
skin, small bowel and bladder were monitored according to a Ger-
man classiﬁcation system that corresponds to the World Health
Organization criteria for chemotherapy toxicity and is compatible
to the Radiation Therapy Oncology Group (RTOG) and European
Organization for Research in Treatment of Cancer (EORTC) acute
and late radiation morbidity scoring criteria [27]. After implemen-
tation of the NCI Common Toxicity Criteria (CTC), version 2.0 in
2000, toxicity grades were reevaluated retrospectively for ﬁnal
analyses (Supplementary Table S1) [28].
For these analyses, the highest CTC scores for treatment-associ-
ated hematologic toxicity, skin reaction, enteritis, or cystitis were
assessed for every patient and correlated with survival parameters.Follow-up
Follow-up visits over a total of ﬁve years were scheduled at
three-month intervals for the ﬁrst two years, then at six-month
intervals. Each visit consisted of a physical examination, a com-
plete blood count, and blood chemistry. Rigid rectoscopy, abdomi-
nal ultrasound, contrast enhanced computed tomography of the
abdomen and pelvis as well as chest radiography were conducted
according to guidelines of the German Cancer Society [29,30]. In
case of local or distant recurrence, histological conﬁrmation was
encouraged. Acceptable alternative evaluation criteria were the
sequential enlargement of a mass in radiological assessments. Fol-
low-up assessments beyond ﬁve years, not speciﬁed in the study
protocol, were performed on a patient-to-patient basis, and addi-
tional information was collected from the participating hospitals
and general practitioners using additional case report forms as de-
scribed recently [7].Statistical analysis
Within the CAO/ARO/AIO-94 trial 799 of 823 enrolled patients
met the inclusion criteria and were randomly assigned to
preoperative (n = 404 patients) or postoperative CRT (n = 395
patients) (intent-to-treat-population), as recently reported [7].
According to the actual treatment population (Supplementary CON-
SORT diagram) 406 patients received preoperative CRT followed by
TME-surgery, and 248 patientswere treatedwith postoperative CRT
after TME-surgery. In 145 patients, postoperative CRT was not
applied [2,7]. Therefore, the following toxicity analyses were
performed in the subset of 654 eligible patients who were actually
treated with CRT.
The survival endpoints were deﬁned as followed: TTR was
determined according to events deﬁned as local or distant recur-
rences. OS was calculated as the time interval between randomiza-
tion and death of any reason or day of last follow-up. All survival
analyses were calculated with the Kaplan–Meier method and dif-
ferences were displayed using the log-rank test. Hazard ratios
and 95% conﬁdence intervals (CIs) were computed based on the
Cox proportional hazards model. Multivariate analyses were per-
formed using the Cox proportional hazards model on the parame-
ters treatment (pre- or postoperative CRT), grade of toxicity,
gender and age as risk factors for cancer recurrence or death. The
parameter treatment was deﬁned based on the actual treatment
received. Associations among clinical categorical variables (e.g.
gender versus treatment) were assessed using the Fisher’s Exact
Test. Furthermore, associations of categorial and continuous vari-
ables (e.g. gender versus age) were determined using the Wilcoxon
Test for two group comparisons or the Kruskal–Wallis Test for mul-
tigroup comparisons. All statistical analyses were performed using
the R statistical computing software (Version: 2.14.1) [31]. Survival
analyses were performed using Kaplan–Meier analyses from the R
package survival and signiﬁcance was estimated using the log-rank
test. Multivariate survival analyses were performed using the Cox
proportional hazards model. A two-sided p-value of less than or
equal to 0.05 was considered signiﬁcant.Results
Patient and treatment characteristics
In the intergroup CAO/ARO/AIO-94 phase III trial 823 patients
were enrolled (Supplementary CONSORT diagram). Of these, 24 pa-
tients were excluded as they did not meet the inclusion criteria
(n = 15) or refused to participate (n = 9) in the trial. The remaining
799 patients were randomly assigned to receive either preopera-
tive CRT (n = 404) or postoperative CRT (n = 395). In both treat-
Table 1
All treated patients and tumor characteristics in relation to gender.
Analyzed study population:
n = 799
Pre- or postoperative CRT (n = 654)
Male n = 457
(%)
Female n = 197
(%)
p-
Value
Age (yr)
Median 61 60 0.98
Range 30–76 29–74
Distance from anal verge
0 to <5 cm 119 (26.1) 57 (28.9) 0.23
5 to <10 cm 212 (46.4) 79 (40.1)
10–16 cm 108 (23.6) 56 (28.4)
Unknown 18 (3.9) 5 (2.6)
TNM stage
pCR/stage 0 25 (5.5) 11 (5.6) 0.88
(y)p I 82 (19.0) 31 (15.7)
(y)p II 140 (30.6) 64 (32.5)
(y)p III 171 (37.4) 78 (39.6)
(y)p IV 33 (7.2) 11 (5.6)
Unknown/no surgery 6 (1.3) 2 (1.0)
Type of resection
Low anterior 286 (62.6) 138 (70.1) 0.26
Intersphincteric 40 (8.8) 14 (7.1)
Abdominoperineal 126 (27.6) 44 (22.3)
Other 1 (0.2) 1 (0.5)
None 4 (0.8) 0 (0)
Unknown 0 (0) 0 (0)
Completeness of local resection
Complete local resection (R0) 436 (95.4) 191 (97.0) 0.36
Incomplete resection (R1) 11 (2.4) 1 (0.5)
Incomplete resection (R2) 2 (0.4) 1 (0.5)
(R2) 3 (0.7) 1 (0.5)
Completeness of scheduled radiotherapy
Preoperative complete 283 (96.6) 108 (95.6) 0.15
Postoperative complete 154 (93.9) 77 (91.7)
Completeness of scheduled chemotherapy
Preoperative complete 267 (95.0) 101 (89.4) 0.22
Postoperative complete 145 (83.5) 69 (82.1)
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Fig. 1. Kaplan–Meier-curves displaying time to recurrence and overa
50 Gender affects toxicity in CRT of rectal cancerment arms 18 and 20 patients, respectively, requested for a change
in therapy. Finally, in 406 patients preoperative CRT was applied
according to study protocol followed by TME-surgery (n = 402).
Postoperative CRT was performed in 248 of the allocated 393 pa-
tients after TME-surgery. In 145 patients postoperative CRT was
not given due to the histopathological conﬁrmation of <UICC stages
II in 75 patients and of UICC stages IV in 19 patients. Additionally,
51 patients did not receive postoperative CRT due to complications
or refusal/institutional errors after surgery. Thus, 654 patients (197
women and 457 men) treated with CRT were assessable for analy-
ses focusing on treatment-associated toxicity.
As shown in the CONSORT diagram, preoperative CRT was ap-
plied in 113 (57.4%) female patients and postoperative CRT in 84
(42.6%), respectively. In 293 (64.1%) male patients preoperative
CRT was given, while 164 (35.9%) men were treated with postoper-
ative CRT. Table 1 summarizes patients‘ characteristics according
to actual treatment received.
Of all patients who had received CRT, 108 (95.6%) of the 113 fe-
male and 283 (96.6%) of the 293 male patients received the in-
tended dose of preoperative RT, whereas postoperative RT was
fully applied in 77 (91.7%) of female and 154 (93.9%) of male pa-
tients, respectively (Table 1). Accordingly, 101 (89.4%) of the wo-
men and 267 (95.0%) of the men received full dose of the
concomitant CT preoperatively. Postoperatively, the full dose of
CT was administered to 69 female (82.1%) and 145male (83.5%) pa-
tients (Table 1).
Follow-up, events and OS according to gender
After a median follow-up of 134 months (range, 90–184) for all
450 surviving patients of the total study population (n = 799), the
10-year OS and TTR rates in women were 62.8% and 72.4%, respec-
tively, with a trend toward higher survival rates compared to men
(OS: 58.4%, p = 0.066; TTR: 65.6%, p = 0.088; Fig. 1) [7].
Of all 654 patients who were treated with CRT, 370 (56.6%)
were still alive at the last follow-up. Of these 370 patients, all
(100%) were followed for at least 5 years, 360 (97%) for at least
8 years, and 261 (71%) for at least 10 years. A total of 280 deaths
occurred, of which 180 (64.29%) deaths were related to rectal can-
cer. No long-term follow-up data were available for 4 patients.0 50 100 150
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Table 2
Overall hematologic toxicity as well as maximum acute organ toxicity of intestine,
bladder and skin according to gender and treatment arm.
Acute toxicity grade (CTC) Male Female p-Value
Acute hematologic toxicity in relation to gender
Leukopenia
0 288 (63.0) 109 (55.3) 0.007
1 90 (19.7) 46 (23.4)
2 32 (7.0) 26 (13.2)
3 3 (0.7) 4 (2.0)
4 3 (0.7) 0 (0.0)
Missing 41 (9.0) 12 (6.1)
Thrombocytopenia
0 406 (88.8) 183 (92.9) 0.222
1 5 (1.1) 2 (1.0)
2 2 (0.4) 0 (0.0)
3 3 (0.7) 0 (0.0)
4 1 (0.2) 0 (0.0)
Missing 40 (8.8) 12 (6.1)
Anemia
0 371 (81.2) 143 (72.6) 0.0002
1 36 (7.9) 38 (19.3)
2 7 (1.5) 3 (1.5)
3 2 (0.4) 1 (0.5)
4 0 (0.0) 0 (0.0)
Missing 41 (9.0) 12 (6.1)
Overall Hematologic toxicity
0 259 (56.7) 87 (44.2) 0.0007
1 110 (24.1) 67 (34.0)
2 39 (8.5) 26 (13.2)
3 6 (1.3) 5 (2.5)
4 3 (0.7) 0 (0.0)
Missing 40 (8.8) 12 (6.1)
Acute organ toxicity of intestine, bladder and skin in relation to gender
Maximum per patient, both arms
0 31 (6.8) 7 (3.6) <0.001
1 157 (34.4) 33 (17.0)
2 123 (26.9) 73 (37.6)
3 136 (29.7) 74 (38.1)
4 7 (1.5) 7 (3.6)
Missing 3 (0.7) 3 (1.5)
Maximum per patient, preoperative arm
0 16 (5.5) 5 (4.4) 0.016
1 111 (37.9) 26 (23.0)
2 71 (24.2) 37 (32.7)
3 89 (30.4) 40 (35.4)
4 3 (1.0) 3 (2.7)
Missing 3 (1.0) 2 (1.8)
Maximum per patient, postoperative arm
0 15 (9.1) 2 (2.4) <0.001
1 46 (28.0) 7 (8.3)
2 52 (31.7) 36 (42.8)
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operative or postoperative CRT had recurrent disease, of which 165
(79.3%) patients had distant metastases alone, 34 (16.4%) in combi-
nation with local recurrence, and 9 (4.3%) patients had isolated lo-
cal recurrence.
Acute toxicity, age, gender, and treatment
Based on all 654 CRT patients, overall hematologic toxicity (leu-
kopenia, anemia, and thrombocytopenia) was signiﬁcantly higher
in female patients (p < 0.001) as shown in Table 2. Especially tran-
sient leucopenia (WHO grade I–III) and mild anemia (WHO grade I)
occurred more often in female patients, whereas severe leucopenia
WHO grade IV was restricted to men. Additional analysis did not
reveal any correlation between the occurrence of hematologic
toxicity and age (Kendall´s correlation coefﬁcient 0.034 resulting
in a p-value of 0.34).
The maximum acute organ toxicity grades recorded for the skin,
bladder, and intestine, were used to create box plots showing
toxicity grades in relation to gender and age (Supplementary
Fig. S1). Remarkably, there was no apparent correlation between
patients´ age and acute organ toxicity (p = 0.97). Conversely,
severity of acute organ toxicity was signiﬁcantly higher in female
patients, as shown in Table 1 for the entire cohort (p < 0.001)
as well as for the preoperative (p = 0.016) and postoperative
(p < 0.001) treatment cohorts, respectively. The main impact on
this distribution resulted from toxicity of the intestine, whereas
skin toxicity showed only a trend for higher incidences and grades
in female patients (p = 0.091). The bladder toxicity showed no
differences regarding gender (p = 0.46).
Treatment associated hematologic (p = 0.0007) as well as
maximum acute organ toxicity (p < 0.001) was higher in female pa-
tients than in men in both treatment arms (p = 0.016 and
p < 0.001). The detailed distribution of treatment related acute tox-
icity is summarized in Table 2.
TTR and OS according to acute toxicity
Fig. 2 displays Kaplan–Meier analyses for OS and TTR rates for
all 654 patients according to the highest acute organ toxicity score
for at least one item of skin, bladder, or intestine toxicity. There
was no apparent correlation between hematologic or organ toxic-
ity and OS or TTR. Interestingly, the lowest OS rates were observed
in patients without any acute toxicity (no toxicity versus toxicity
groups: p = 0.0271).3 47 (28.8) 34 (40.5)
4 4 (2.4) 4 (4.8)
Missing 0 (0.0) 1 (1.2)
Intestinal toxicity per patient, both arms
0 117 (25.9) 25 (12.9) <0.001
1 193 (42.8) 52 (26.8)
2 120 (26.6) 89 (45.9)
3 20 (4.4) 24 (12.4)
4 1 (0.2) 4 (2.0)
Bladder toxicity per patient both arms
0 303 (67.0) 123 (64.4%) 0.46
1 122 (27.0) 53 (27.8%)
2 23 (5.1) 15 (7.9%)
3 4 (0.9) 0 (0.0%)
4 0 (0.0) 0 (0.0%)
Skin toxicity per patient, both arms
0 100 (22.1) 37 (19.3) 0.091
1 159 (35.2) 55 (28.7)
2 62 (13.7) 36 (18.8)
3 125 (27.7) 61 (31.8)
4 6 (1.3) 3 (1.6)Inﬂuence of acute organ toxicity on OS and TTR
Furthermore, gender-speciﬁc survival analyses revealed that OS
in male patients was signiﬁcantly lower when no acute organ tox-
icities occurred (Fig. 2, p = 0.0187). When TTR was analyzed, there
was only a trend for male patients without any toxicity, although
these results were not signiﬁcant (p = 0.522). In detail, after a fol-
low-up of 10 years, 6.6% (n = 30) of all male patients suffered from
local failure and 31.5% (n = 144) developed distant metastases. For
female patients, the results were 6.6% (n = 13) and 27.9% (n = 55),
respectively. Remarkably, for women no correlation was detectable
between grade of toxicity and OS (p = 0.88) or TTR (p = 0.992).
In addition to the univariate analyses, multivariate analyses for
OS, but not for TTR, revealed that acute organ toxicity as well as
age were signiﬁcant prognostic parameters for OS, independent
of pre- or postoperative CRT and gender (Table 3).
Discussion
This unplanned add-on study of participants of the German
CAO/AIO/ARO-94 trial was motivated by intriguing results derivedfrom our monocentric analysis on 196 patients with locally ad-
vanced rectal cancer (UICC stages II and III) [26]. In this cohort
study we found signiﬁcantly more high-grade acute organ toxici-
52 Gender affects toxicity in CRT of rectal cancerties in women undergoing preoperative CRT. To validate our ﬁnd-
ings, the present conﬁrmatory analysis was conducted, analyzing
654 patients of the CAO/ARO/AIO-94-trial based on actual treat-
ment received and providing a median follow-up of 10 years. We
again identiﬁed gender as a signiﬁcant risk factor for CRT-induced
acute toxicity: the overall maximum organ toxicity was signiﬁ-
cantly higher in female compared to male patients.
In the overall trial population, the 10-year OS rates were in
trend higher in women than in men (62.7% vs. 58.4%; p = 0.066)
which could be expected since life expectancy in general is higher
in women compared to men. In this context, signiﬁcant age-related
sex differences in the incidence and maybe also in the prognosis of
colorectal cancer were described recently while the underlying
reasons remain unillucidated, so far [32].
Moreover, OS in male patients was signiﬁcantly lower when no
acute organ toxicities occurred, and acute organ toxicity turned out
to be a signiﬁcant prognostic parameter for OS in multivariate
analysis. The lack of acute toxicity therefore seemed to be associ-
ated with higher chance of dying owing to causes other then rectal
cancer.
Even if the statistical power of this restrospective add-on
analysis can be discussed, the possible underlying reasons for
lower OS in patients without any acute toxicity remain unclear.0 50 100 150
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Es
tim
at
ed
 p
ro
po
rti
on
p=0.992
maxtox 0. 7 patients.
maxtox 1−4. 187 patients.
# risk 7 5 4187 127 110 35
maxtox
maxtox 
fem
0 50 100 150
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Es
tim
at
ed
 p
ro
po
rti
on
time to recurrence [months]
p=0.522
maxtox 0. 31 patients.
maxtox 1−4. 423 patients.
# risk 31 16 14 3423 290 229 64
maxto
maxtox
m
Fig. 2. Kaplan–Meier-curves displaying time to recurrence andAll patients received the same treatment according to the trial
protocol, and compliance with all components of multimodality
treatment, including RT, CTx, and TME-surgery (Table 1), was
comparable between men and women. Patients’ age was equally
distributed in both genders and did not correlate with hematologic
toxicity or acute organ toxicity.
In the literature, only few reports on RT or CRT of solid cancers
have speciﬁcally addressed either gender-speciﬁc risks for treat-
ment-related organ toxicity or a correlation of gender and toxicity
with long-term outcomes. Dahl et al. [33] described a signiﬁcant
correlation between acute side-effects to the normal bowel and
sensitivity of rectal carcinomas to preoperative RT. In this study,
comprising 159 patients, high-grade acute toxicity was signiﬁ-
cantly related to tumor regression at the time of surgery compared
to patients without high-grade bowel toxicity.
Interestingly, in anal cancer, also a signiﬁcant correlation be-
tween CRT-induced acute toxicity and improved loco-regional tu-
mor response as well as long-term outcome was observed [34].
Detailed analyses showed high-grade acute organ toxicity as an
independent prognostic factor in multivariate analysis and a bene-
ﬁt for female patients reaching a signiﬁcantly better loco-regional
control rate in comparison to male patients (5-years: 87% vs. 53%;
p = 0.01). 0
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Table 3
Multivariate analyses of the time to recurrence and overall survival according to
actual treatment, CTC grade of acute organ toxicity, gender and age.
Variables Hazard ratio [95% CI] p-Value
TTR univariate
Treatment arm (postoperative) 1.11 [0.84–1.47] 0.45
Grade of toxicity (I–IV) 0.84 [0.47–1.50] 0.55
Gender (male) 1.28 [0.96–1.69] 0.089
Age 1.00 [0.99–1.01] 0.934
TTR multivariate
Treatment arm (postoperative) 1.13 [0.86–1.50] 0.376
Grade of toxicity (I–IV) 0.85 [0.47–1.53] 0.593
Gender (male) 1.16 [0.85–1.58] 0.347
Age 1.00 [0.98–1.01] 0.838
OS univariate
Treatment arm (postoperative) 1.06 [0.84–1.35] 0.61
Grade of toxicity (I–IV) 0.61 [0.39–0.95] 0.029
Gender (male) 1.25 [0.99–1.58] 0.066
Age 1.03 [1.02–1.05] <0.001
OS multivariate
Treatment arm (postoperative) 1.08 [0.85–1.38] 0.521
Grade of toxicity (I–IV) 0.62 [0.40–0.96] 0.034
Gender (male) 1.13 [0.87–1.48] 0.359
Age 1.03 [1.02–1.05] <0.001
CI, conﬁdence interval; TTR, time to recurrence; OS, overall survival.
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acute hematologic and organ toxicity in our analyses, especially
for the intestine, could be explained by enzyme levels of dihydro-
pyrimidine dehydrogenase (DPD). This enzyme is the rate-limiting
factor in the catabolism of 5-FU. DPD has been reported to corre-
late with the toxicity and effectiveness of 5-FU-based cancer treat-
ment. Yamashita et al., among others, found signiﬁcantly lower
levels of DPD in females in a cohort of 97 colorectal cancer patients
[35]. Subsequently, lower DPD-levels in women could result in
higher plasma levels of 5-FU causing higher toxicity and also a bet-
ter long-term outcome. Thus, it may be clinically useful to individ-
ually adjust chemotherapy dosages to DPD-activity and/or plasma-
levels of 5-FU in future clinical trials [36].
Our analyses were conducted in the setting of the CAO/ARO/
AIO-94-phase-III-trial which established the present gold-standard
in the treatment of locally advanced rectal cancer: preoperative 5-
FU-based CRT followed by TME-surgery, and adjuvant 5-FU che-
motherapy. The aim of currently ongoing trials, e.g. CAO/ARO/
AIO-04-phase-III-trial [16], is either to integrate more effective
CTx regimens to preoperative RT or to include multi-agent CTx as
inductive chemotherapy approaches [12,37], in order to enhance
the rate of pCR and in particular, to reduce the occurrence of dis-
tant metastases leading to improved TTR as well as OS [11,13].
Any intensiﬁcation of treatment components bears the risk of
high-grade acute organ toxicity [21,22,38,39]. Thus, basic pre-treat-
ment parameters that allow the identiﬁcation of subgroups of pa-
tients at a higher risk of severe acute organ toxicity would help to
improve the clinical management of these patients. Additionally,
it should enforce optimized standard of supportive care to success-
fully complete the planned multimodality therapy. Even though in
this add-on evaluation of the CAO/ARO/AIO-94-trial a high propor-
tion of 96.3% (RT) and 90.6% (CTx) of patients received the planned
dosages preoperatively versus 93.1% (RT) and 86.3% (CTx)
postoperatively these are comparably lower in other studies [40].
To increase the treatment adherence even under intensiﬁed
treatment protocols [13,16,18], further optimization of every part
of the multimodal treatment is mandatory. Therefore, like the al-
ready standardized use of a belly-board during RT [41], new and
more protective techniques such as intensity modulated
volumetric arcs or irradiation with protons [42] might further
reduce the exposure of organs at risk and of normal tissues [43]
without compromising tumor control rates, in the future.In conclusion, our results suggest that basic patient characteris-
tics such as gender may predict the occurrence of CRT-induced
acute organ toxicity that affects long-term outcome. Together with
further identiﬁed reliable biomarkers this may help to tailor treat-
ment modalities in a cost effective manner. Finally, this may lead
to early preventative interventions to avoid severe adverse effects
during multimodality treatment and ultimately to improve pa-
tients‘ outcomes.
Role of funding source
This study was funded by a grant from the German Cancer Aid
(Deutsche Krebshilfe) and by the German Research Foundation
(DFG) within the clinical research unit (KFO) 179–2
(www.kfo179.de) subproject 5 and 6.
Conﬂict of interest
The authors have declared no conﬂicts of interest.
Acknowledgment
This manuscript was edited by the ‘‘American Journal Experts’’
editorial service.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2013.05.
009.
References
[1] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA
Cancer J Clin 2009;59:225–49.
[2] Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative
chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731–40.
[3] MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet
1993;341:457–60.
[4] Gastrointestinal Tumor Study Group. Radiation therapy and ﬂuorouracil with
or without semustine for the treatment of patients with surgical adjuvant
adenocarcinoma of the rectum. J Clin Oncol 1992;10:549–57.
[5] Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy
for high-risk rectal carcinoma. N Engl J Med 1991;324:709–15.
[6] Sauer R, Fietkau R, Wittekind C, et al. Adjuvant vs. neoadjuvant
radiochemotherapy for locally advanced rectal cancer: the German trial CAO/
ARO/AIO-94. Colorectal Dis 2003;5:406–15.
[7] Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative
chemoradiotherapy for locally advanced rectal cancer: results of the German
CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11
years. J Clin Oncol 2012;30:1926–33.
[8] Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative
radiotherapy in rectal cancer. N Engl J Med 2006;355:1114–23.
[9] Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or
without concurrent ﬂuorouracil and leucovorin in T3–4 rectal cancers: results
of FFCD 9203. J Clin Oncol 2006;24:4620–5.
[10] Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early
response indicator for patients with rectal cancer. J Clin Oncol
2012;30:1770–6.
[11] Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and
oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-
deﬁned poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010;11:241–8.
[12] Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of
concomitant chemoradiotherapy followed by surgery and adjuvant
capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX
followed by concomitant chemoradiotherapy and surgery in magnetic
resonance imaging-deﬁned, locally advanced rectal cancer: Grupo cancer de
recto 3 study. J Clin Oncol 2010;28:859–65.
[13] Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative
chemoradiation with or without oxaliplatin in locally advanced rectal cancer:
pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol
2011;29:2773–80.
[14] Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase
II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and
preoperative radiotherapy with or without cetuximab followed by total
54 Gender affects toxicity in CRT of rectal cancermesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin
Oncol 2012;30:1620–7.
[15] Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant
chemoradiotherapy regimens for locally advanced rectal cancer: results of the
phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638–44.
[16] Roedel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and
postoperative chemotherapy with ﬂuorouracil and oxaliplatin versus
ﬂuorouracil alone in locally advanced rectal cancer: initial results of the
German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol
2012;13:679–87.
[17] Roh MS, Yothers GA, O’Connell MJ. The impact of capecitabine and oxaliplatin
in the preoperative multimodality treatment in patients with carcinoma of the
rectum: NSABP R-04. J Clin Oncol 2011;29. Suppl; abstr 3503.
[18] Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD
12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol
2012;28(10):1638–44.
[19] Rodel C, Martus P, Papadoupolos T, et al. Prognostic signiﬁcance of tumor
regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol
2005;23:8688–96.
[20] Eich HT, Stepien A, Zimmermann C, et al. Neoadjuvant radiochemotherapy and
surgery for advanced rectal cancer: prognostic signiﬁcance of tumor
regression. Strahlenther Onkol 2011;187:225–30.
[21] Aschele C, Friso ML, Pucciarelli S, et al. A phase I–II study of weekly oxaliplatin,
5-ﬂuorouracil continuous infusion and preoperative radiotherapy in locally
advanced rectal cancer. Ann Oncol 2005;16:1140–6.
[22] Machiels JP, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin,
capecitabine and external beam radiotherapy in patients with rectal cancer:
the RadiOxCape study. Ann Oncol 2005;16:1898–905.
[23] Fietkau R, Rodel C, Hohenberger W, et al. Rectal cancer delivery of
radiotherapy in adequate time and with adequate dose is inﬂuenced by
treatment center, treatment schedule, and gender and is prognostic parameter
for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys
2007;67:1008–19.
[24] Ghadimi BM, Grade M, Diﬁlippantonio MJ, et al. Effectiveness of gene
expression proﬁling for response prediction of rectal adenocarcinomas to
preoperative chemoradiotherapy. J Clin Oncol 2005;23:1826–38.
[25] Liersch T, Grade M, Gaedcke J, et al. Preoperative chemoradiotherapy in locally
advanced rectal cancer: correlation of a gene expression-based response
signature with recurrence. Cancer Genet Cytogenet 2009;190:57–65.
[26] Wolff HA, Conradi LC, Schirmer M, et al. Gender-speciﬁc acute organ toxicity
during intensiﬁed preoperative radiochemotherapy for rectal cancer.
Oncologist 2011;16:621–31.
[27] Seegenschmiedt MH, Sauer R. The systematics of acute and chronic radiation
sequelae. Strahlenther Onkol 1993;169:83–95.
[28] Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an
improved reference for grading the acute effects of cancer treatment: impact
on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13–47.[29] Pichlmaier H, Hossfeld DK, Sauer R. Konsenus der CAO, AIO und ARO zur
adjuvanten Therapie bei Kolon- und Rektumkarzinom vom 11. März 1994.
Chirurg 1994;65:411–2.
[30] Schmiegel W, Reinacher-Schick A, Arnold D, et al. Update S3-guideline
‘‘colorectal cancer’’ 2008. Z Gastroenterol 2008;46:799–840.
[31] R Development Core Team, FfSC. A language and environment for statistical
computing 2011. http://www.R-project.org.
[32] Purim O, Gordon N, Brenner B. Cancer of the colon and rectum: potential
effects of sex–age interactions on incidence and outcome. Med Sci Monit
2013;19:203–9.
[33] Dahl O, Horn A, Mella O. Do acute side-effects during radiotherapy predict
tumour response in rectal carcinoma? Acta Oncol 1994;33:409–13.
[34] Wolff HA, Raus I, Jung K, et al. High-grade acute organ toxicity as a positive
prognostic factor in primary radiochemotherapy for anal carcinoma. Int J
Radiat Oncol Biol Phys 2011;79:1467–78.
[35] Yamashita K, Mikami Y, Ikeda M, et al. Gender differences in the
dihydropyrimidine dehydrogenase expression of colorectal cancers. Cancer
Lett 2002;188:231–6.
[36] Gamelin E, Delva R, Jacob J, et al. Individual ﬂuorouracil dose adjustment based
on pharmacokinetic follow-up compared with conventional dosage: results of
a multicenter randomized trial of patients with metastatic colorectal cancer. J
Clin Oncol 2008;26:2099–105.
[37] Rodel C, Hofheinz R, Liersch T. Rectal cancer: state of the art in 2012. Curr Opin
Oncol 2012;24:441–7.
[38] de Castro G, Snitcovsky Jr IM, Gebrium EM, et al. High-dose cisplatin
concurrent to conventionally delivered radiotherapy is associated with
unacceptable toxicity in unresectable, non-metastatic stage IV head and
neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2007;264:1475–82.
[39] Franzmann EJ, Lundy DS, Abitbol AA, Goodwin WJ. Complete hypopharyngeal
obstruction by mucosal adhesions: a complication of intensive
chemoradiation for advanced head and neck cancer. Head Neck
2006;28:663–70.
[40] Bujko K, Glynne-Jones R, Bujko M. Does adjuvant ﬂuoropyrimidine-based
chemotherapy provide a beneﬁt for patients with resected rectal cancer who
have already received neoadjuvant radiochemotherapy? A systematic review
of randomised trials. Ann Oncol 2010;21:1743–50.
[41] Vorwerk H, Hermann RM, Christiansen H, Liersch T, Hess CF, Weiss E. A special
device (double-hole belly board) and optimal radiation technique to reduce
testicular radiation exposure in radiotherapy of rectal cancer. Radiother Oncol
2007;84:320–7.
[42] Wolff HA, Wagner DM, Conradi LC, et al. Irradiation with protons for the
individualized treatment of patients with locally advanced rectal cancer: a
planning study with clinical implications. Radiother Oncol 2012;102:30–7.
[43] Hennies S, Wolff HA, Jung K, et al. Testicular radiation dose after multimodal
curative therapy for locally advanced rectal cancer. Inﬂuence on hormone
levels, quality of life, and sexual functioning. Strahlenther Onkol
2012;188:926–32.
